Rising prevalence of human papillomavirus related oropharyngeal cancer in Australia over the last 2 decades
|
|
- Marsha Washington
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Rising prevalence of human papillomavirus related oropharyngeal cancer in Australia over the last 2 decades Angela Hong, PhD, 1,2 * C. Soon Lee, MD, 1,3 Deanna Jones, BAppSci, 4 Anne-Sophie Veillard, MS, 5 Mei Zhang, MD, 1,2 Xiaoying Zhang, PhD, 1 Robert Smee, MBBS, 6 June Corry, MBBS, 7 Sandro Porceddu, MBBS, 8 Christopher Milross, MD, 1,2 Michael Elliott, MPhil, 9 Jonathan Clark, MBBS, 1,9 Barbara Rose, PhD 4 1 Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia, 2 Department of Radiation Oncology, Lifehouse, Sydney, New South Wales, Australia, 3 Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, 4 Department of Infectious Diseases and Immunology, The University of Sydney, Sydney, New South Wales, Australia, 5 NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia, 6 Department of Radiation Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia, 7 Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, 8 Cancer Services, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia, 9 Sydney Head and Neck Cancer Institute, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. Accepted 10 December 2014 Published online 25 June 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI /hed ABSTRACT: Background. This study provides Australian data on the characteristics of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) over the last 2 decades. Methods. The HPV status of 515 patients with oropharyngeal SCC diagnosed between 1987 and 2010 was determined by HPV E6-targeted multiplex real time polymerase chain reaction assay (PCR) and p16 immunohistochemistry. Results. The HPV positivity rate increased from 20.2% ( ) to 63.5% ( ). Among HPV-positive oropharyngeal SCC over the study period, the median age increased from 55.4 years to 59.8 years (p 5.004) and there was a trend of an increasing proportion of never smokers (19.2% to 34.0%). The use of radiation therapy (RT) in patients with HPV-positive oropharyngeal cancer increased from 26.9% to 68.1% (p 5.007) and we also observed a trend of improved outcomes. Conclusion. Our data show a rising prevalence of HPV-positive oropharyngeal SCC in Australia over the last 2 decades. These patients with HPV-positive oropharyngeal SCC are now presenting at an older age and about one third have never smoked. VC 2015 Wiley Periodicals, Inc. Head Neck 38: , 2016 KEY WORDS: human papillomavirus (HPV), oropharyngeal cancer, head and neck cancer INTRODUCTION Head and neck squamous cell carcinoma is the sixth most common cancer worldwide 1 and the incidence of oropharyngeal squamous cell carcinoma (SCC) is increasing in Western countries despite declining tobacco use. 2 6 We have previously reported that this increase in Australia is likely attributable to a rise in the proportion of oropharyngeal SCC caused by human papillomavirus (HPV); from 19% ( ) to 47% ( ) to 66% ( ). 3 This trend is particularly apparent in the younger age group and parallels findings in other developed countries where HPV positivity rates as high as 72% have been reported. 7 The biological characteristics of HPV-positive oropharyngeal SCC are distinct from those of HPV-negative oropharyngeal SCC with respect to expression of the p16ink4a (p16), and genetic profiles, including the frequency of mutations in the p53 gene. 8,9 Epidemiologically, *Corresponding author: A. Hong, Central Clinical School, The University of Sydney, Level 6, Blackburn Building, New South Wales, 2006 Australia. angela.hong@sydney.edu.au Contract grant sponsor: This study was supported by a grant from the Cure Cancer Australia. it has been reported that patients with HPV-positive oropharyngeal SCC tend to be younger, less likely to have a history of tobacco and alcohol use, and tend to have a higher number of sexual partners, in particular oral sexual partners, than patients with HPV-negative oropharyngeal SCC. 10 Furthermore, HPV-positive oropharyngeal SCC is associated with markedly better survival, despite a tendency for higher grade and more advanced nodal disease. 11 This study extends our previous work 3 by including patients treated for oropharyngeal SCC at 10 large teaching hospitals in Australia over the last 2 decades. We sought evidence of change in HPV status relative to tobacco exposure, personal characteristics, treatment patterns, and outcomes over the study period. The purpose of this study was to gain new insight into the changing epidemiology of oropharyngeal SCC in Australia. MATERIALS AND METHODS Incidence of oropharyngeal cancer in Australia Cancer incidence data were obtained from the National Cancer Statistics Clearing House database of the Australian Institute of Health and Welfare (AIHW; gov.au), which incorporates data from the 8 Australian HEAD & NECK DOI /HED MAY
2 HONG ET AL. TABLE 1. Patient characteristics by human papillomavirus status. Characteristic HPV-positive (n 5 220) HPV-negative (n 5 295) p value for heterogeneity Age at diagnosis, y (mean, range) 55.8 (31 89) 61 (39 83) <.0001 Sex.6336 Female 49 (22.3%) 71 (24.1%) Male 171 (77.7%) 224 (75.9%) Smoking status <.0001 Nonsmoker 59 (26.8%) 14 (4.7%) Ex-smoker 86 (39.1%) 90 (30.5%) Current smoker 75 (34.1%) 191 (64.7%) Alcohol status (missing 5 77).0148 Nondrinker 32 (17.4%) 21 (8.3%) Ex-drinker 15 (8.2%) 25 (9.8%) Drinker 137 (74.5%) 208 (81.9%) Primary tumor site.0009 Tonsil 181 (82.3%) 222 (75.3%) Base of tongue 29 (13.2%) 30 (10.2%) Other oropharyngeal 10 (4.5%) 43 (14.6%) Grade < (9.1%) 60 (20.3%) 2 76 (34.5%) 161 (54.6%) (56.4%) 74 (25.1%) T classification (missing 5 2) (25.1%) 32 (10.9%) 2 77 (35.2%) 107 (36.4%) 3 56 (25.6%) 104 (35.4%) 4 31 (14.2%) 51 (17.3%) N classification (missing 5 4) < (20.9%) 146 (50.2%) 1 38 (17.3%) 61 (21.0%) (50.9%) 71 (24.4%) 3 24 (10.9%) 13 (4.5%) TNM classification (missing 5 1) < (2.7%) 26 (8.8%) 2 18 (8.2%) 63 (21.4%) 3 47 (21.4%) 92 (31.3%) (67.7%) 113 (38.4%) Abbreviation: HPV, human papillomavirus. state and territory cancer registries. We used the data for oropharyngeal SCC incorporating the base of tongue (C01), tonsil (C09), and other sites within the oropharynx (C10) and laryngeal cancer as a smoking-related head and neck cancer for comparison. Study population The study cohort comprised 520 consecutive patients with primary oropharyngeal SCC treated with curative intent at 10 hospitals in Australia between 1987 and The study was approved by Sydney Local Health Service Ethics committees (Protocol x ). The oropharynx is defined as palatine tonsil (tonsillar fossa, tonsillar pillar), base of tongue, soft palate, and posterior walls of the oropharynx. Patient selection was based on the availability of tumor and clinicopathological data. The HPV status of the oropharyngeal SCC was not determined at the time of diagnosis and therefore treatment decisions were not based on HPV status. Laboratory studies An HPV-positive tumor was defined as one testing positive for both HPV DNA and p16 expression to ensure virus causality. 12 Presence and type of HPV DNA were determined on two to six 4 to 5 mm sections of formalin-fixed paraffin-embedded tumor using an HPV E6-based multiplex real time polymerase chain reaction assay (PCR) modified from Stanley and Szewczuk. 13 This assay detects and identifies 21 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73, 82, 53, 6, 11, and 26). Stringent precautions were taken to avoid cross-contamination and water blanks placed after every fifth tube to detect contamination. DNA was extracted using the QIAmp RNA viral mini kit (Qiagen, Germany). Measured amounts of equine herpesvirus were used to monitor DNA extraction efficiency and removal of PCR inhibitors. The presence of cancer cells was confirmed by pathologist C.S.L. in hematoxylin-eosin stained sections cut after those for HPV analysis. Expression of p16 was determined by semiquantitative immunohistochemistry using an autostainer (Dako, Australia), the JC2 clone (Neomarkers, USA) (1/200) and the EnVision Flex Dual Link horseradish peroxidase/dab visualization system (Dako, Australia). Staining was evaluated by 2 investigators, including a pathologist, as per our established protocol. 14 Statistical analyses Associations between HPV status and clinicopathological characteristics were assessed using a 2-sample t test 744 HEAD & NECK DOI /HED MAY 2016
3 RISING PREVALENCE OF HPV-RELATED OROPHARYNGEAL CANCER FIGURE 1. (A) Locoregional recurrence. (B) Event free survival (C) Overall survival. HPV, human papillomavirus. for the continuous variable and chi-square tests for categorical variables. The time trend in the proportion of oropharyngeal cancers testing HPV-positive was analyzed using the binary test for trend. Times to locoregional failure, death from oropharyngeal cancer, and death from any cause were calculated from the date of diagnosis. Locoregional recurrence was defined as clinical, radiological, and/or pathological evidence of recurrence at the primary site or in the regional nodal area. The Kaplan Meier method was used to construct time-to-event curves. RESULTS Patient characteristics This 23-year study was divided into 4 periods (1995 and prior, , , and ). Five patients with HPV DNA-positive but p16-negative oropharyngeal SCC were excluded from the analysis. The characteristics of the 515 patients included in the study are shown in Table 1. Overall 220 of the 515 patients (42.7%) had HPV-positive oropharyngeal SCC. There was a gradual increase in the prevalence of HPV-positive oropharyngeal SCC from 20.2% in the 1987 to 1995 period to 63.5% in the 2006 to 2010 period. At diagnosis, patients with HPV-positive oropharyngeal SCC were significantly younger, more likely to be never smokers and nondrinkers, and to have a tonsillar primary, lower T stage and higher N stage (hence, higher TNM stage; FIGURE 2. (A) Incidence of oropharyngeal cancer in Australia from 1991 to 2009 (from Australian Institute of Health and Welfare [AIHW]). (B) Incidence of laryngeal cancer in Australia from 1991 to 2009 (from AIHW). HEAD & NECK DOI /HED MAY
4 HONG ET AL. TABLE 2. The baseline characteristics of patients with HPV-positive tumors by study period. All years (n 5 220) Before 1995 (n 5 26) (n 5 80) (n 5 67) (n 5 47) p value for heterogeneity (p value for trend) Mean age at diagnosis, y (range) 55.8 (31 89) 55.4 (34 77) 52 (31 76) 57.0 (35 89) 59.8 (32 86).0040 (.003) Sex.9267 Female 49 (22.3%) 6 (23.1%) 19 (23.8%) 13 (19.4%) 11 (23.4%) (.86) Male 171 (77.7%) 20 (76.9%) 61 (76.3%) 54 (80.6%) 36 (76.6%) Smoking status.6101 Non smoker 59 (26.8%) 5 (19.2%) 18 (22.5%) 20 (29.9%) 16 (34.0%) (.19) Ex-smoker 86 (39.1%) 12 (46.2%) 31 (38.8%) 28 (41.8%) 15 (31.9%) Current smoker 75 (34.1%) 9 (34.6%) 31 (38.8%) 19 (28.4%) 16 (34.0%) Alcohol status (missing 5 36).5574 Non smoker 32 (17.4%) 6 (28.6%) 8 (13.8%) 13 (21.3%) 5 (11.4%) (.63) Ex-drinker 15 (8.2%) 1 (4.8%) 4 (6.9%) 5 (8.2%) 5 (11.4%) Drinker 137 (74.5%) 14 (66.7%) 46 (79.3%) 43 (70.5%) 34 (77.3%) Primary tumor site.0058 Tonsil 181 (82.3%) 21 (80.8%) 70 (87.5%) 57 (85.1%) 33 (70.2%) Base of tongue 29 (13.2%) 4 (15.4%) 6 (7.5%) 5 (7.5%) 14 (29.8%) Other oropharyngeal 10 (4.5%) 1 (3.8%) 4 (5.0%) 5 (7.5%) 0 (0.0%) Grade (9.1%) 3 (11.5%) 9 (11.3%) 4 (6.0%) 4 (8.5%) (.11) 2 76 (34.5%) 10 (38.5%) 29 (36.3%) 25 (37.3%) 12 (25.5%) (56.4%) 13 (50.0%) 42 (52.5%) 38 (56.7%) 31 (66.0%) T classification (missing 5 1) (25.1%) 5 (19.2%) 13 (16.5%) 20 (29.9%) 17 (36.2%) (.001) 2 77 (35.2%) 9 (34.6%) 25 (31.6%) 24 (35.8%) 19 (40.4%) 3 56 (25.6%) 8 (30.8%) 24 (30.4%) 18 (26.9%) 6 (12.8%) 4 31 (14.2%) 4 (15.4%) 17 (21.5%) 5 (7.5%) 5 (10.6%) N classification (20.9%) 5 (19.2%) 21 (26.3%) 11 (16.4%) 9 (19.1%) (.67) 1 38 (17.3%) 4 (15.4%) 17 (21.3%) 10 (14.9%) 7 (14.9%) (50.9%) 13 (50.0%) 32 (40.0%) 39 (58.2%) 28 (59.6%) 3 24 (10.9%) 4 (15.4%) 10 (12.5%) 7 (10.4%) 3 (6.4%) TNM classification (2.7%) 2 (7.7%) 2 (2.5%) 1 (1.5%) 1 (2.1%) (.20) 2 18 (8.2%) 1 (3.8%) 7 (8.8%) 4 (6.0%) 6 (12.8%) 3 47 (21.4%) 6 (23.1%) 23 (28.8%) 12 (17.9%) 6 (12.8%) (67.7%) 17 (65.4%) 48 (60.0%) 50 (74.6%) 34 (72.3%) Treatment.0068 RT (1/- CTX) 112 (50.9%) 7 (26.9%) 42 (52.5%) 31 (46.3%) 32 (68.1%) (.007) Surgery 1/- adjuvant RT (1/- CTX) 108 (49.1%) 19 (73.1%) 38 (47.5%) 36 (53.7%) 15 (31.9%) Abbreviations: RT, radiotherapy; CTX, chemotherapy. Table 1). The median follow-up of the whole cohort was 48.5 months and 233 patients had died at the time of last follow-up. Patients with HPV-positive oropharyngeal SCC had significantly better outcomes in terms of locoregional recurrence, event-free survival, and overall survival (Figure 1A 1C). Increasing incidence of oropharyngeal squamous cell carcinoma in Australia Data from AIHW showed that the incidence of oropharyngeal SCC in Australia doubled from 322 cases per year in 1991 to 665 cases per year in 2009 (Figure 2A). This increase was seen in both sexes but was more apparent in men (from 235 cases in 1991 to 530 cases in 2009). In comparison, the incidence of laryngeal SCC (a smoking-related head and neck cancer) was stable in both men and women during the same period (Figure 2B). Time trends by human papillomavirus status Among patients with HPV-positive oropharyngeal SCC, the median age increased from 55.4 years in the 1987 to 1995 period to 59.8 years in the 2006 to 2010 period (p 5.004; Table 2). The proportion that was never smokers at the time of diagnosis increased from 19.2% (1995 and prior) to 34.0% ( ; p value for trend 5.19 for never smokers vs ex-smokers vs current smokers and p value for trend 5.08 for never smokers vs smokers). Over time, patients with HPV-positive oropharyngeal SCC were also more likely to have base of tongue primary sites (15.4% vs 29.8%; p 5.006) and lower T classification (in the more recent study period [19.2% vs 36.2%; p 5.069]). In patients with HPV-negative oropharyngeal SCC, there was no significant difference in the median age at diagnosis, the proportion of nonsmokers (4.7%), the location of the primary site, or T classification over the study period (Table 3). 746 HEAD & NECK DOI /HED MAY 2016
5 RISING PREVALENCE OF HPV-RELATED OROPHARYNGEAL CANCER TABLE 3. The baseline characteristics of patients with HPV-negative tumors by study period. Characteristic All years (n 5 295) Before 1995 (n 5 103) (n 5 94) (n 5 71) (n 5 27) p value for heterogeneity (p value for trend) Mean age at diagnosis, y 61.0 (39 83) 59.5 (42 77) 61.7 (39 82) 61.2 (41 83) 63.3 (45 82).1748 (.059) Gender.2122 Female 71 (24.1%) 32 (31.1%) 20 (21.3%) 13 (18.3%) 6 (22.2%) (.088) Male 224 (75.9%) 71 (68.9%) 74 (78.7%) 58 (81.7%) 21 (77.8%) Smoking status.7311 Non smoker 14 (4.7%) 5 (4.9%) 2 (2.1%) 5 (7.0%) 2 (7.4%) (.38) Ex-smoker 90 (30.5%) 28 (27.2%) 32 (34.0%) 22 (31.0%) 8 (29.6%) Current smoker 191 (64.7%) 70 (68.0%) 60 (63.8%) 44 (62.0%) 17 (63.0%) Alcohol status (missing 5 41).0197 Non drinker 21 (8.3%) 9 (10.3%) 3 (3.8%) 7 (11.1%) 2 (8.0%) (.22) Ex-drinker 25 (9.8%) 6 (6.9%) 9 (11.4%) 3 (4.8%) 7 (28.0%) Drinker 208 (81.9%) 72 (82.8%) 67 (84.8%) 53 (84.1%) 16 (64.0%) Primary tumor site.4650 Tonsil 222 (75.3%) 78 (75.7%) 75 (79.8%) 51 (71.8%) 18 (66.7%) Base of tongue 30 (10.2%) 11 (10.7%) 10 (10.6%) 7 (9.9%) 2 (7.4%) Other oropharyngeal 43 (14.6%) 14 (13.6%) 9 (9.6%) 13 (18.3%) 7 (25.9%) Grade (20.3%) 26 (25.2%) 18 (19.1%) 11 (15.5%) 5 (18.5%) (.071) (54.6%) 54 (52.4%) 54 (57.4%) 41 (57.7%) 12 (44.4%) 3 74 (25.1%) 23 (22.3%) 22 (23.4%) 19 (26.8%) 10 (37.0%) T classification (missing 5 1) (10.9%) 15 (14.6%) 8 (8.6%) 4 (5.6%) 5 (18.5%) (.37) (36.4%) 38 (36.9%) 29 (31.2%) 30 (42.3%) 10 (37.0%) (35.4%) 39 (37.9%) 39 (41.9%) 19 (26.8%) 7 (25.9%) 4 51 (17.3%) 11 (10.7%) 17 (18.3%) 18 (25.4%) 5 (18.5%) N classification (missing 5 4) (50.2%) 60 (58.3%) 45 (48.4%) 30 (43.5%) 11 (42.3%) (.073) 1 61 (21.0%) 20 (19.4%) 18 (19.4%) 16 (23.2%) 7 (26.9%) 2 71 (24.4%) 19 (18.4%) 22 (23.7%) 23 (33.3%) 7 (26.9%) 3 13 (4.5%) 4 (3.9%) 8 (8.6%) 0 (0.0%) 1 (3.8%) TNM classification (missing 5 1) (8.8%) 14 (13.6%) 6 (6.5%) 2 (2.8%) 4 (14.8%) (.048) 2 63 (21.4%) 24 (23.3%) 18 (19.4%) 16 (22.5%) 5 (18.5%) 3 92 (31.3%) 36 (35.0%) 29 (31.2%) 19 (26.8%) 8 (29.6%) (38.4%) 29 (28.2%) 40 (43.0%) 34 (47.9%) 10 (37.0%) Treatment.9142 RT (1/- CTX) 126 (42.7%) 42 (40.8%) 41 (43.6%) 30 (42.3%) 13 (48.1%) (.58) Surgery 1/- adjuvant RT (1/- CTX) 169 (57.3%) 61 (59.2%) 53 (56.4%) 41 (57.7%) 14 (51.9%) Abbreviations: RT, radiotherapy; CTX, chemotherapy. Treatment over the study period There was an increase in the use of definitive radiation therapy (RT; with or without chemotherapy) and a decrease in the use of surgery (with or without adjuvant therapy) over the study period (p ). Overall, RT was used in 27.6% of patients in the earliest period (1995 and prior), but the rate had more than doubled (58.6%) by the latest period ( ). This increase was seen only in patients with HPV-positive oropharyngeal SCC, 26.9% in the 1987 to 1995 period to 68.1% in the 2006 to 2010 period (p 5.007). In contrast, there was no significant change in the treatment approach in patients with HPV-negative oropharyngeal SCC (p 5.914). Outcomes over the study period During the 23-year study period, there was a trend toward better locoregional control in patients with HPVpositive oropharyngeal SCC (p 5.075; Figure 3A). Similarly, the event-free survival and overall survival also improved in the more recent study periods (Figure 3B and 3C). However, the outcomes of patients with HPVnegative oropharyngeal SCC did not change during the study period (Figure 4). DISCUSSION This study has provided new insight into the changing epidemiology of oropharyngeal SCC in Australia. Data collected from more than 500 patients treated at 10 teaching hospitals in Australia over the last 2 decades showed a steady increase in the proportion of HPV-positive oropharyngeal SCC (from 20.2% to 63.5% over the study period). This is consistent with our earlier smaller series 3 and parallels findings from other developed countries. 2,15 18 Overall results strongly support the concept HEAD & NECK DOI /HED MAY
6 HONG ET AL. FIGURE 3. Outcomes of patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (SCC) over the 4 study periods ( and prior; ; ; and ). (A) Locoregional recurrence. (B) Event-free survival. (C) Overall survival. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] that HPV accounts for the increasing incidence of oropharyngeal SCC seen in Australia and in other developed countries. 18,19 The effect of declining tobacco use in our community on the epidemiology of oropharyngeal SCC was a major focus of this study. Many studies have shown that patients with HPV-positive oropharyngeal SCC are less likely to have a history of tobacco use than those with HPV-negative oropharyngeal SCC. 20,21 In our cohort, patients with HPV-positive oropharyngeal SCC were increasingly likely to be never smokers at diagnosis (from 19.2% to 34.0% over the study period). Our current rate of never smokers with HPV-positive oropharyngeal SCC is similar to that reported from other Western countries. 20,22 The role of mutagens in tobacco as a co-factor to HPV in the development of oropharyngeal SCC, and the interaction between HPV and smoking in prognosis and response to treatment are not fully understood. Previous studies have shown that among patients with HPVpositive oropharyngeal SCC, smokers had poorer outcomes than never smokers. 21,23 Our findings have important research and public health implications. However, smoking remains a major risk factor for oropharyngeal SCC worldwide, underscoring the need for prevention strategies targeted toward tobacco and alcohol use. Interestingly, the median age at diagnosis for our patients with HPV-positive oropharyngeal SCC increased over time. We speculate that this could be related to the declining proportion of smokers in this cohort, therefore less exposure to the potential co-carcinogen tobacco. Overall, the median age of patients with HPV-positive oropharyngeal SCC was still less than that of patients with HPV-negative oropharyngeal SCC. HPV-negative oropharyngeal SCC has traditionally been associated with tobacco use (and alcohol abuse), and smoking patterns among this group did not change over time, with only about 5% being never smokers, 30% ex-smokers, and 60% current smokers at the time of diagnosis. In line with our previous studies 24,25 and other published data, 26 the tonsil was the predominant primary site for HPV-positive oropharyngeal SCC. Interestingly, the proportion of base of tongue primaries increased over time and there was also a trend for lower T stage at presentation. Further longitudinal studies will be needed to 748 HEAD & NECK DOI /HED MAY 2016
7 RISING PREVALENCE OF HPV-RELATED OROPHARYNGEAL CANCER FIGURE 4. Outcomes of patients with human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (SCC) over the 4 study periods ( and prior; ; ; and ). (A) Locoregional recurrence. (B) Event-free survival. (C) Overall survival. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] confirm these trends and to identify underlying factors. This study found no evidence of changes in the epidemiology of HPV-negative oropharyngeal SCC over the study period. It is unlikely that the difference in HPV prevalence in the different periods is due to a different analytical sensitivity of our HPV DNA PCR in different periods as the cycle threshold values did not differ between the years. We also tested for p16 expression with immunohistochemistry, which our controls have shown is unaffected by sample DNA quality. P16 is a cyclin-dependent kinase inhibitor and is induced as a consequence of inhibition of retinoblastoma protein activity by the HPV E7 oncoprotein. The reason for the rapid increase in prevalence of HPV-positive oropharyngeal SCCs remains elusive. One explanation may be a change in sexual behavior (ie, the increasing practice of oral sex and increasing numbers of lifetime sex partners). Data from Europe and the United States suggest that the number of lifetime sexual partners has increased over recent decades. 27,28 As the HPV infection usually takes more than 10 years to progress from infection to malignancy, a temporal change in sexual behavior could explain the increased incidence observed in HPV-positive oropharyngeal SCC. There is a geographic variation in terms of incidence rates of oropharyngeal SCC. 10 This likely reflects wide variability in the prevalence of established risk behaviors and modifiers. Our study lacks details of sexual activity, drug use, and socioeconomic status to show any change in these risk factors during the study period. Although HPV vaccination offers the potential to stem this trend, it will not have an impact on the incidence of HPV-positive oropharyngeal SCC for decades. Given the rising trends and the approximately 40-year lag time between infection and manifestation of the disease, HPVpositive oropharyngeal SCC will be a problem for the foreseeable future. In the interim, the HPV-positive oropharyngeal SCC epidemic will have tremendous implications for health care resources; these typically younger, healthier patients have a high chance of surviving their disease, 23 and they will have to live with the late effects of treatment for many decades. Our results showed a trend in improved outcomes in patients with HPV-positive oropharyngeal SCC over the HEAD & NECK DOI /HED MAY
8 HONG ET AL. study period but not in patients with HPV-negative oropharyngeal SCC. This could be the result of the increasing use of combined chemotherapy and RT, but our data do not allow us to draw definitive conclusions on the best treatment for patients with HPV-positive oropharyngeal SCC. The choice of treatment in our study cohort was not based on the HPV status (the HPV status was not available in the majority) and the increasing use of RT was only seen in the patients with HPV-positive oropharyngeal SCC. This is likely because of their younger age and higher nodal stage at diagnosis. Given the favorable prognosis in this cohort, assessment of the HPV status of oropharyngeal SCC should be routine in clinical practice. However, the best treatment regimen for HPV-positive oropharyngeal SCC has not been defined and tremendous interest has been expressed in deescalating therapy to decrease toxicity. Potential deescalation strategies include the use of transoral robotic surgery, reduced doses of radiation or chemotherapy (or both), or avoidance of chemotherapy entirely for low-risk patients. One such trial is the TROG study, which aims to compare the treatment-related side effects of RT with concurrent cisplatin or cetuximab regimens in HPV-positive oropharyngeal SCC. In conclusion, our data show a rising prevalence of HPV-positive oropharyngeal SCC in Australia over the last 2 decades, from 20.2% (1995 and prior) to 63.5% ( ). These patients with HPV-positive oropharyngeal SCC are now presenting at an older age and about one-third have never smoked. Acknowledgments The authors thank the clinicians at all the participating hospitals. REFERENCES 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, CA Cancer J Clin 2005;55: Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26: Hong AM, Grulich AE, Jones D, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010;28: Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83: Hocking JS, Stein A, Conway EL, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPVassociated oropharyngeal cancers. Br J Cancer 2011;104: Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29: Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008;22: Marur S, D Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11: Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24: Gillison ML, Castellsague X, Chaturvedi A, et al. Eurogin roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer 2014;134: Hong AM, Martin A, Armstrong BK, et al. Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol 2013;24: Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121: Stanley KK, Szewczuk E. Multiplexed tandem PCR: gene profiling from small amounts of RNA using SYBR Green detection. Nucleic Acids Res 2005;33:e Hong A, Jones D, Chatfield M, et al. HPV status of oropharyngeal cancer by combination HPV DNA/p16 testing: biological relevance of discordant results. Ann Surg Oncol 2013;20 Suppl 3:S450 S N asman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125: Nichols AC, Palma DA, Dhaliwal SS, et al. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Curr Oncol 2013;20: Rietbergen MM, Leemans CR, Bloemena E, et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer 2013; 132: Evans M, Newcombe R, Fiander A, et al. Human papillomavirusassociated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. BMC Cancer 2013;13: Chaturvedi AK, Anderson WF, Lortet Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013;31: Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363: Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010;16: Gillison ML, D Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16- negative head and neck cancers. J Natl Cancer Inst 2008;100: Hong AM, Martin A, Chatfield M, et al. Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma. Int J Cancer 2013;132: Hong A, Zhang M, Veillard AS, et al. The prognostic significance of hypoxia inducing factor 1-A in oropharyngeal cancer in relation to human papillomavirus status. Oral Oncol 2013;49: Hong AM, Dobbins TA, Lee CS, et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010;103: Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16- negative oropharyngeal cancer. J Clin Oncol 2012;30: Agius PA, Pitts MK, Smith AM, Mitchell A. Sexual behaviour and related knowledge among a representative sample of secondary school students between 1997 and Aust N Z J Public Health 2010;34: Bajos N, Bozon M, Beltzer N, et al. Changes in sexual behaviours: from secular trends to public health policies. AIDS 2010;24: HEAD & NECK DOI /HED MAY 2016
HPV-Related Head and Neck Squamous Cancers
2015 Wisconsin Comprehensive Cancer Control Summit Aligning Partners, Priorities, and the Plan HPV-Related Head and Neck Squamous Cancers MCW Department of Otolaryngology and Communication Sciences MCW
More informationCase Report Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx in a Married Couple
Case Reports in Otolaryngology Volume 2016, Article ID 8481235, 4 pages http://dx.doi.org/10.1155/2016/8481235 Case Report Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
More informationObjectives. HPV Classification. The Connection Between Human Papillomavirus and Oropharyngeal Cancer 6/19/2012
The Connection Between Human Papillomavirus and Oropharyngeal Cancer Jennifer L. Cleveland, DDS, MPH Dental Officer/Epidemiologist OSAP Annual Symposium June 23, 2012 Atlanta, GA National Center for Chronic
More informationABSTRACT INTRODUCTION
/, Vol. 7, No. 47 PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-pd1 clinical trials Angela M Hong 1, Ricardo E Vilain
More informationHPV and Head and Neck Cancer
William C. Faquin, MD, PhD, FCAP Director, Head and Neck Pathology Massachusetts General Hospital Associate Professor of Pathology Harvard Medical School HPV and Head and Neck Cancer A number of testing
More informationEpidemiological Characteristics of Oral and Oropharyngeal Squamous Cell Carcinoma H.S. van Monsjou
Epidemiological Characteristics of Oral and Oropharyngeal Squamous Cell Carcinoma H.S. van Monsjou Summary The epidemiology of head and neck cancer has shown remarkable changes in past decades (chapter
More informationThe Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer. William H.
The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer William H. Westra From the Department of Pathology and Otolaryngology/Head
More informationFirst of all, the pathophysiology
Welcome. My name is Eric Sturgis and I m a Professor in Head and Neck Surgery with a joint appointment in the Department of Epidemiology at The University of Texas MD Anderson Cancer Center. And today
More informationSmoking, human papillomavirus infection, and p53 mutation as risk factors in oropharyngeal cancer: a case-control study
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Smoking, human papillomavirus infection, and p53 as risk factors in oropharyngeal cancer: a case-control study PKS Chan *, JSY Chor, AC Vlantis, TL
More informationHPV is the most common sexually transmitted infection in the world.
Hi. I m Kristina Dahlstrom, an instructor in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center. My lecture today will be on the epidemiology of oropharyngeal
More informationHPV and Head and Neck Cancer: What it means for you and your patients
HPV and Head and Neck Cancer: What it means for you and your patients Financial Disclosure: None November 8, 2013 Steven J. Wang, MD Associate Professor Department of Otolaryngology-Head and Neck Surgery
More informationOral HPV infection and the changing epidemiology in head and neck cancer
Oral HPV infection and the changing epidemiology in head and neck cancer Daniel Beachler, PhD, MHS Johns Hopkins School of Public Health Department of Epidemiology Southwest Region s Dental PBRN Meeting
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationReporting HPV related carcinomas of the head and neck. dr. Nina Zidar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia
Reporting HPV related carcinomas of the head and neck dr. Nina Zidar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia Conflict of interest/funding X None Company: Product royalties
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationUpdate on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12.
Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12. Non Cervical Cancers with an HPV aetiology 1. Anal 2. Penile 3. Vulval 4. Vaginal 5. Component of head
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationHumaan Papillomavirus en hoofd/halskanker. Pol Specenier
Humaan Papillomavirus en hoofd/halskanker Pol Specenier pol.specenier@uza.be Humaan Papillomavirus en hoofd/halskanker Hoofd/halskanker: incidentie en oorzaken Oropharynx carcinoom Incidentie HPV HPV en
More informationHead and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S.
Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Associate Professor Division of Head and Neck Surgery Department of Otolaryngology-Head and
More informationHuman Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
More informationHead and Neck SCC. HPV in Tumors of the Head and Neck. Overview. Role of HPV in Pathogenesis of Head & Neck Tumors
HPV in Tumors of the Head and Neck Christina Kong, M.D. Associate Professor, Stanford Dept of Pathology Director, Cytopathology Laboratory & Cytopathology Fellowship ckong@stanford.edu Head and Neck SCC
More informationUpdate of the role of Human Papillomavirus in Head and Neck Cancer
Update of the role of Human Papillomavirus in Head and Neck Cancer 2013 International & 12 th National Head and Neck Tumour Conference Shanghai, 11 13 Oct 2013 Prof. Paul KS Chan Department of Microbiology
More informationAnatomy of Head of Neck Cancer
Anatomy of Head of Neck Cancer J. Robert Newman, MD The ENT Center of Central GA H&N Cancer Overview Most categories of cancer are represented in the H&N Squamous cell carcinoma most common mucosal cancer
More informationCirculating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: Updated analysis with 10-year follow-up
Chapter Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: Updated analysis with 10-year follow-up Famke L. Schneiders, Renée C.G. de Bruin, Fons
More informationESMO Perceptorship H&N cancer Epidemiology, Anatomy and Workup 16 March 2018
ESMO Perceptorship H&N cancer Epidemiology, Anatomy and Workup 16 March 2018 Dr. Victor Ho-Fun Lee MBBS, MD, FRCR, FHKCR, FHKAM (Radiology) Clinical Associate Professor Department of Clinical Oncology
More informationGreater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute
2008 ANNUAL REPORT Greater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute Cancer Registry Report The Cancer Data Management System/ Cancer Registry collects data on all types of cancer
More informationORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence
ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;
More informationTrends in oral and oropharyngeal (mouth) cancer incidence in Wales,
Trends in oral and oropharyngeal (mouth) cancer incidence in Wales, 2001-2013 November 2015 Dental Public Health Team, Public Health Wales Welsh Cancer Intelligence and Surveillance Unit, Public Health
More informationA Case Review: Treatment-Naïve Patient with Head and Neck Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPatterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma
ORIGINAL ARTICLE Patterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma Matthew E. Spector, MD, 1 K. Kelly Gallagher, MD, 1 Emily Bellile, MS,
More informationNotice of Faculty Disclosures
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director of Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital FNA OF SQUAMOUS CYSTS OF THE HEAD AND
More informationTriple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer
Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer Dylan F. Roden, MD, MPH 1,2 ; David Schreiber, MD 2,3 ; and Babak Givi, MD 1,2 BACKGROUND: Concurrent chemoradiation (CCRT) and upfront
More informationAssociation of Human Papilloma Virus Type 16 and 18 with Squamous Cell Carcinoma in Oral Cavity and Oropharynx
Association of Human Papilloma Virus Type 16 and 18 with Squamous Cell Carcinoma in Oral Cavity and Oropharynx *Saklain MA, 1 Rahman MZ, 2 Nasreen M, 3 Haque AE, 4 Sarker JN 5 Oral squamous cell carcinoma
More informationEvaluation and Management of Head and Neck Cancer in Patients with Fanconi anemia David I. Kutler, M.D., F.A.C.S.
Evaluation and Management of Head and Neck Cancer in Patients with Fanconi anemia David I. Kutler, M.D., F.A.C.S. Residency Site Director Weill Cornell Medical Center Associate Professor Division of Head
More informationHPV Analysis of Head and Neck Squamous Cell Carcinomas based on Fine-Needle. Aspiration Specimens. William H. Westra M.D.
HPV Analysis of Head and Neck Squamous Cell Carcinomas based on Fine-Needle Aspiration Specimens William H. Westra M.D. The Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore Maryland
More informationOral Cavity and Oropharynx Cancer Trends
Oral Cavity and Oropharynx Cancer Trends Darien Weatherspoon, DDS, MPH Diplomate, American Board of Dental Public Health Program Officer, National Institute of Dental and Craniofacial Research National
More informationOral Cancer Risk and Detection
Oral Cancer Risk and Detection Evan M. Graboyes, MD Assistant Professor Department of Otolaryngology-Head & Neck Surgery Cancer Control Program, Hollings Cancer Center Medical University of South Carolina
More informationJMSCR Vol 05 Issue 08 Page August 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i8.04 Association of uncommon sexual practices
More informationTrends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study
Trends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study Lorraine Shack PhD, Harold Y. Lau MD, Longlong Huang MSc, Corinne Doll
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationIncidence of HPV-Associated Head and Neck Cancers by Sub-site Among Diverse Racial/Ethnic Populations in the United States
Incidence of HPV-Associated Head and Neck Cancers by Sub-site Among Diverse Racial/Ethnic Populations in the United States Louisiana Tumor Registry LSUHSC School of Public Health Lauren Cole, MPH Linda
More informationMANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS
MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS Kyle Arneson, MD PhD Avera Medical Group Radiation Oncology Avera Cancer Institute 16 th Annual Oncology Symposium September
More informationINTRODUCTION MATERIALS AND METHODS
ORIGINAL ARTICLE Human papillomavirus integration pattern and demographic, clinical, and survival characteristics of patients with oropharyngeal squamous cell carcinoma Ming Yann Lim, MD, 1,3 Kristina
More informationPredictive Accuracy of First Post-Treatment PET/CT in HPV-Related Oropharyngeal Squamous Cell Carcinoma
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Predictive Accuracy of First Post-Treatment in HPV-Related Oropharyngeal Squamous Cell Carcinoma Yekaterina
More informationHuman Papillomavirus Testing in Head and Neck Carcinomas
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview
More informationHead and Neck Cancer Update Sandro V Porceddu
Head and Neck Cancer Update Sandro V Porceddu Director, Radiation Oncology Research Princess Alexandra Hospital, Brisbane Associate Professor, University of Queensland President, Trans Tasman Radiation
More informationNew Chapter in Our Understanding of Human Papillomavirus-Related Head and Neck Cancer
Published Ahead of Print on September 15, 2014 as 10.1200/JCO.2014.56.5754 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2014.56.5754 JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A
More informationBackground HPV causes virtually all cervical cancers HPV-16, Integration of viral oncogenes E6 and E7 Relationship between HPV and cervical cancer wou
Case-Control Control Study of Human Papillomavirus avi and Oropharyngeal Cancer D Souza, DSouza, et al. NEJM, May 2007 Tony Sung Julia Beaver Journal Club September 9, 2009 Background HPV causes virtually
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationCyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer
Lin et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:23 ORIGINAL RESEARCH ARTICLE Open Access Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer Rui Jun
More informationOROPHARYNX CANCER. Anthony Zeitouni, MD, FRCSC. Co-Lead, Head Neck Cancer Rossy Cancer Network
OROPHARYNX CANCER Anthony Zeitouni, MD, FRCSC Co-Lead, Head Neck Cancer Rossy Cancer Network CFPC CoI Templates: Slide 1 FACULTY/PRESENTER DISCLOSURE Faculty: Dr Anthony Zeitouni Relationships with commercial
More informationTongue carcinoma: Case series and demographic analysis
Abstract Masoud Naderpour 1, Safar Farajnia 2, Gholamreza Bayazian 3, Monireh Halimi 4, Samad Ghiasi 5, Leila Rahbarnia 6 Case Series BACKGROUND: Oral tongue squamous cell carcinoma (SCC) accounts for
More informationORIGINAL ARTICLE. Predicting HPV Status in Head and Neck Cancer. The Predictive Value of Sociodemographic and Disease Characteristics
ORIGINAL ARTICLE Predicting HPV Status in Head and Neck Cancer The Predictive Value of Sociodemographic and Disease Characteristics J. Kenneth Byrd, MD; Christina S. T. Wilhoit, CCRP; M. Taylor Fordham,
More informationThe Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers
CLINICAL REVIEW The Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers Kevin A. Moore II, MD, and Vikas Mehta, MD While the rate of head and neck cancer
More informationSAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 4 FEBRUARY 1 28 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Incidence Trends for Human Papillomavirus Related and Unrelated Oral Squamous Cell Carcinomas in the United States
More informationPublished online 28 September 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI /hed.23173
ORIGINAL ARTICLE Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with
More informationDisclosures. HPV and Head and Neck Cancer NONE 5/8/2018
Bill Lydiatt, MD EMBA Chair Department of Surgery Methodist Hospital Clinical Professor of Surgery Creighton University HPV and Head and Neck Cancer Disclosures NONE 1 OVERVIEW Traditional Head and Neck
More informationOncologist. The. Outcomes Research. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis
The Oncologist Outcomes Research Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis DIANNE PULTE, a,b HERMANN BRENNER a a Division of Clinical Epidemiology
More informationSurvival Benefit of Chemotherapy in Oropharyngeal Cancer Patients Treated with. Surgery and Post-Operative Radiation. Fawaz Mohammed Makki
Survival Benefit of Chemotherapy in Oropharyngeal Cancer Patients Treated with Surgery and Post-Operative Radiation by Fawaz Mohammed Makki A thesis submitted in partial fulfillment of the requirements
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationThomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
More informationHHS Public Access Author manuscript Oral Oncol. Author manuscript; available in PMC 2015 May 26.
Epidemiology of HPV-associated oropharyngeal cancer Kristen B. Pytynia, MD, MPH a,*, Kristina R. Dahlstrom, PhD a, and Erich M. Sturgis, MD, MPH a,b a Department of Head and Neck Surgery, The University
More informationSQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY
ORIGINAL ARTICLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY Yi-Shing Leu 1,2,3 *, Yi-Fang Chang 4, Jehn-Chuan Lee 1, Chung-Ji Liu 2,5,6, Hung-Tao Hsiao 7, Yu-Jen Chen 8, Hong-Wen Chen 8,9,
More informationHuman Papillomavirus Infection in 674 Chinese Patients with Laryngeal Squamous Cell Carcinoma
RESEARCH ARTICLE Human Papillomavirus Infection in 674 Chinese Patients with Laryngeal Squamous Cell Carcinoma Yanan Xu 1,2,4, Suru Liu 1,4, Hongliang Yi 1,4, Jiadong Wang 2,4 *, Pin Dong 3,4 *, Xiaoyan
More informationPrevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer
ORIGINAL ARTICLE Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer Shamir P. Chandarana, MD, MSc, 1 Julia S. Lee, MS,
More informationManagement of oropharyngeal cancer: a cross-sectional review of institutional practice at a large Canadian referral centre
Wilson et al. Journal of Otolaryngology - Head and Neck Surgery 214, 4:1 ORIGINAL RESEARCH ARTICLE Open Access Management of oropharyngeal cancer: a cross-sectional review of institutional practice at
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationSurgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationHUMAN PAPILLOMAVIRUS
HUMAN PAPILLOMAVIRUS HUMAN PAPILLOMAVIRUS The Human Papillomavirus (HPV) is responsible for 60% of cancers of the throat including base of the tongue and tonsils. AN OVERVIEW TO HUMAN PAPILLOMAVIRUS Human
More informationQuality of Life in Head and Neck Cancer Patients: Impact of HPV and Primary Treatment Modality
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Quality of Life in Head and Neck Cancer Patients: Impact of HPV and Primary Treatment Modality Jessica H.
More informationOutcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21 st century
Garden et al. Radiation Oncology 2013, 8:21 RESEARCH Open Access Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21 st century Adam S Garden
More informationPopulation-based validation of the recursive partitioning analysis based staging system for oropharyngeal cancer
ORIGINAL ARTICLE Population-based validation of the recursive partitioning analysis based staging system for oropharyngeal cancer Florence K. Keane, MD, 1 Yu-Hui Chen, MS, MPH, 2 Roy B. Tishler, MD, PhD,
More informationHead and Neck Cancer. Mukund Seshadri DDS, PhD.!
Head and Neck Cancer Mukund Seshadri DDS, PhD Mukund.Seshadri@roswellpark.org 716-845- 1552 Overview Epidemiology Etiology and Risk factors Disease Biology Management Conventional Novel Targeted Therapies
More informationTransoral Robotic Surgery and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16 INK4a on Treatment Outcomes
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Transoral Robotic Surgery and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16 INK4a
More informationCurrent Clinical Trials for Oropharyngeal SCC in the HPV Era
Current Clinical Trials for Oropharyngeal SCC in the HPV Era Dr Caroline Connell Adelaide Radiotherapy Centre Page 1 3 May, 2016 Overview Advent of HPV associated Oropharyngeal SCC aetiology/risk factors
More informationLonger survival in patients with human papillomavirus related head and neck cancer after positive postradiation planned neck dissection
ORIGINAL ARTICLE Longer survival in patients with human papillomavirus related head and neck cancer after positive postradiation planned neck dissection Shao Hui Huang, MSc, MD, MRT(T), 1 Samip Patel,
More informationHuman Papillomavirus in Head and Neck Cancer
Human Papillomavirus in Head and Neck Cancer Adam L. Holtzman, M.D. ACLI Medical Section Meeting 2019 Disclosures Employment Relationship University of Florida Compensation, Remuneration, Funding None
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationTREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy
TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park
More informationLymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer
ORIGINAL ARTICLE Lymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer Jun-Ook Park, MD, PhD, 1 Young-Hoon Joo, MD, PhD, 2 Kwang-Jae Cho, MD, PhD, 2 Min-Sik
More informationOral Cancer. Online Course:
Continuing Education Brought to you by Oral Cancer Course Author(s): Richard C. Jordan, DDS, PhD, FRCD(C) FRCPath CE Credits: 1 hour Intended Audience: Dentists, Dental Hygienists, Dental Assistants, Dental
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationNasopharynx. 1. Introduction. 1.1 General Information and Aetiology
Nasopharynx 1. Introduction 1.1 General Information and Aetiology The nasopharynx is the uppermost, nasal part of the pharynx. It extends from the base of the skull to the upper surface of the soft palate.
More informationCancer of the Head and Neck and. HPV Infection. Andrew Urquhart MD, FACS Dept. Otolaryngology/Head and Neck Surgery Marshfield Clinic
Cancer of the Head and Neck and HPV Infection Andrew Urquhart MD, FACS Dept. Otolaryngology/Head and Neck Surgery Marshfield Clinic Disclaimer I have no relevant financial relationships with the manufacturer(s)
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationClinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationEARLY ONLINE RELEASE
EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationJOURNAL SCAN FOR IJHNS
JOURNAL SCAN FOR IJHNS IJHNS Journal Scan for IJHNS Meta-analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomized Trials and 17,346 Patients Jean-Pierre Pignon A, Aurélie
More informationCorrelation of human papillomavirus status with apparent diffusion coefficient of diffusion-weighted MRI in head and neck squamous cell carcinomas
ORIGINAL ARTICLE Correlation of human papillomavirus status with apparent diffusion coefficient of diffusion-weighted MRI in head and neck squamous cell carcinomas Juliette P. Driessen, MD, 1,5 * Alexander
More informationHead and Neck Cancer: Epidemiology
Head and Neck Cancer: Epidemiology Professor Kevin Harrington Joint Head of Division of Radiotherapy and Imaging The Institute of Cancer Research/The Royal Marsden NIHR Biomedical Research Centre Radiotherapy
More informationHPV-Associated Cancers
HPV-Associated Cancers HPV Vaccination Summit: Debunking Myths and Preventing Cancer Thursday, February 2, 2017 St. Luke s Anderson Center Chris Johnson, MPH Cancer Data Registry of Idaho Outline Human
More information